SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University
September 27, 2022 14:58 ET
|
SEngine Precision Medicine, Inc.
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D...
CURE Media Group Announces 2022 Lung Cancer Heroes Award Winners
September 15, 2022 16:11 ET
|
CURE Media Group
The third-annual awards program will honor three heroes for their outstanding contributions in the field of lung cancer, the deadliest and second most common form of cancer, at a Sept. 23 event during...
Global Immune Checkpoint Inhibitors Market to Surpass US$ 3,902.9 Million by 2030, Says Coherent Market Insights (CMI)
August 29, 2022 08:40 ET
|
CMI
Seattle, Aug. 29, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immune checkpoint inhibitors market is estimated to be valued at US$ 1,444.7 million in 2022 and is...
Doxorubicin Market Revenue to Cross $1,983.40 million by 2028 to Rise at a Stellar CAGR of 6.1% by 2028 | Exclusive Research by The Insight Partners
July 12, 2022 10:54 ET
|
The Insight Partners
New York, July 12, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Doxorubicin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Drug Formulation,...
Monoclonal Antibodies for Oncology Global Market Report 2022
July 08, 2022 05:43 ET
|
Research and Markets
Dublin, July 08, 2022 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies for Oncology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report provides detailed...
Theralase Expands Intellectual Property Portfolio
June 28, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Persbericht Biocartis Group NV: Biocartis kondigt nieuwe overeenkomst aan met AstraZeneca voor de ontwikkeling en marketing van een companion diagnostic test voor Tagrisso®
June 22, 2022 01:00 ET
|
Biocartis NV
PERSBERICHT: 22 juni 2022, 07:00 CEST Biocartis kondigt nieuwe overeenkomst aan met AstraZeneca voor de ontwikkeling en marketing van een companion diagnostic test voor Tagrisso® Mechelen, België,...
Press release Biocartis Group NV: Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
June 22, 2022 01:00 ET
|
Biocartis NV
PRESS RELEASE: 22 June 2022, 07:00 CEST Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso® Mechelen, Belgium, 22 June...
Persbericht Biocartis Group NV: Biocartis kondigt lancering aan van zijn snelle CE-gemarkeerde IVD Idylla™ GeneFusion Panel voor snelle behandelingsbeslissingen in longkanker
June 20, 2022 01:00 ET
|
Biocartis NV
PERSBERICHT: 20 juni 2022, 07:00 CEST Biocartis kondigt lancering aan van zijn snelle CE-gemarkeerde IVD Idylla™ GeneFusion Panel voor snelle behandelingsbeslissingen in longkanker Idylla™...
Press release Biocartis Group NV: Biocartis Announces Launch of its Rapid CE-marked IVD Idylla™ GeneFusion Panel for Fast Treatment Decisions in Lung Cancer
June 20, 2022 01:00 ET
|
Biocartis NV
PRESS RELEASE: 20 June 2022, 07:00 CEST Biocartis Announces Launch of its Rapid CE-marked IVD Idylla™ GeneFusion Panel for Fast Treatment Decisions in Lung Cancer Idylla™ GeneFusion Panel available...